September 24, 2020 — The COVID-19 pandemic has forced clinical trial stakeholders to rethink the paradigm as sponsors adapt to site restrictions, remote monitoring, and updated regulatory guidance. This is especially true in precision medicine programs, which have developed global footprints in order to reach targeted patient populations and rely on specialty labs running complex […]
September 21, 2020 — What does precision medicine actually mean and how can AI and ML impact it? QuartzBio’s Renee Deehan and panelists explore AI and ML’s impact on precision medicine and what the industry needs to do to prepare for it, tackle challenges as they evolve and develop appropriate solutions. Learn More
August 27, 2020 — Machine learning and model-based drug discovery is rapidly becoming the norm. Computational biology is now integrating ‘wet’ in vitro/in vivo and ‘dry’ in silico biology accelerating and saving time and resources, at least in the early stages of drug discovery. This MassBio panel discussion explored the new world of digital biology […]
August 13, 2020 — Cell therapy clinical trials typically generate a significant quantity and diversity of biologic data intended to characterize disease and patient biology, as well as data intended to demonstrate evidence of therapeutic mechanisms. QuartzBio’s Cliff Culver et al., explores the benefits of capturing and integrating molecular biomarker data within clinical trials to […]
July 27, 2020 — QuartzBio’s Tobias Guennel, PhD, presented the following poster, “A Genetic Enrichment Strategy for Delay of Onset of Alzheimer’s Disease Clinical Trials,” at AAIC 2020. Download the poster
July 16, 2020 — Computational approaches using COVID-19 data can be invaluable in quickly generating insights for drug repurposing, target pathway selection, and many other challenges. In this webinar, QuartzBio’s Renee Deehan will discuss how teams are combining deep biological knowledge with computational and machine learning approaches. The global pandemic caused by SARS-CoV-2 has resulted […]
June 8, 2020 — As the QuartzBio team’s efforts have progressed with the selection and integration of SARS-CoV-2 / COVID-19 data sets, I am pleased to share our first public update on analysis. This work builds on an evaluation of IFN-α2b treatment, and supports the rationale that interferons are upregulated as part of the antiviral […]
May 20, 2020 — With new information around SARS-CoV-2 and COVID-19 surfacing on an almost daily basis, we are consistently reminded of the complexity and relatively unknown mechanisms behind why this disease presents with such a varying degree of severity. The impacts of COVID-19 infection on pediatric patients have been of particular concern in recent […]
May 18, 2020 — As the research community is generating data from novel research and looking to leverage prior research (e.g., MERS, SARS), there is significant opportunity to integrate these diverse data sources to create an even more valuable data asset for scientific insight generation. This opportunity requires addressing very real data wrangling challenges.
May 14, 2020 — Modern clinical trials distribute samples to an expanding range of screening labs, specialty labs, and bio-banking facilities. Maintaining visibility into sample collection and data processing too often requires manually comparing inventories from each lab’s LIMS, and then checking against what is expected according to the protocol.
Precision for Medicine is the first biomarker-driven clinical development organization supporting life sciences companies in the use of biomarkers essential to targeting patient treatments. Precision for Medicine is part of Precision Medicine Group, with 3,000 employees in 40 locations.
QUARTZBIO® and the PRECISION QUARTZBIO® logo are registered trademarks of Precision Medicine Group, LLC in the United States and/or other jurisdictions. All rights reserved.
© 2024. All rights reserved.
Precision Medicine Group, LLC.
Privacy Policy | GDPR
Web Design and Development by RainCastle Communications.